Mikhail Blagosklonny Life and Interests in Cancer and Anti-Aging Research

Mikhail Blagosklonny is a well-known scientist with his studies focusing mostly on cancer and aging. His research interests are centered about cancer and targeted cancer therapies that prevent damaging of normal cells. He has an M.D. in internal medicine and a Ph.D. in experimental medicine and cardiology. He earned them at the First Pavlov State Medical University. In 2002, he became the associate professor of medicine at the New York College. He served as a senior scientist on ResearchGate.net at Ordway Research Institute. In 2009, he was appointed as a Professor of Oncology at Roswell Park Cancer Institute.

Dr. Blagosklonny is an author to more than 270 articles and research publications with over 25,000 citations. He is the founding Editor and the Editor-in-Chief of Cell cycle and Oncotarget. Mikhail Blagosklonny is an associate editor of Cancer Biology and Therapy, Cell Death and Differentiation, American Journal of Pathology, and PLOS ONE. Dr. Blagosklonny is the founding member of 700forscience. It consists of experts who have specialized in creating grassroots support systems for biotechnology systems.

Dr. Blagosklonny research work ranges from cellular and molecular biology to clinical investigations including signal transduction, cellular senescence, and anticancer therapeutics. He has come up with a hypothesis on the possible role of Target of Rapamycin signaling in cancer and aging. He proposes the use of the eponymous drug Rapamycin as a useful anti-aging pharmaceutical. Dr. Blagosklonny is known to be a passionate advocate of Rapamycin in longevity studies. He suggests that Rapamycin may be an effective drug against atherosclerosis, osteoporosis, cancer, autoimmune diseases, diabetes, obesity, macular degeneration, Alzheimer’s diseases, hypertension, and hypercoagulation. Source: http://www.nature.com/cdd/about/biographies.html

In his research on aging, he tries to find out if the continuous developmental program in the body that causes diseases of aging can be pharmacologically switched off before becoming hyper-functional and damaging. Mikhail Blagosklonny tries to identify a molecular target which causes cell senescence, organism aging, and diseases of aging. He is the writer of the hyperfunction theory of aging and anti-cancer approaches. They are commonly referred to as chemotherapeutic engineering and cell cyclotherapy.